|
|||||
|
|
Rapid progression of fibrosing alveolitis and thyrotoxicosis after antithymocyte globulin therapy for aplastic anemia |
|
| Authors: | A. Zomas J. C. W. Marsh N. K. Harrison S. L. Hyer S. S. Nussey G. Knee A. G. Wilson A. Lakhani E. C. Gordon-Smith |
| Affiliation: | (1) Academic Department of Haematology and Cytogenetics, Royal Marsden Hospital, Downs Road, SM2 5PT Sutton, Surrey, UK;(2) Department of Haematology, St. George's Hospital, London, UK;(3) Department of Chest Medicine, St. George's Hospital, London, UK;(4) Department of Biochemical Medicine, St. George's Hospital, London, UK;(5) Department of Histopathology, St. George's Hospital, London, UK;(6) Department of Radiology, St. George's Hospital, London, UK;(7) Department of Haematology, Farnborough, Kent, UK |
| Abstract: | Antithymocyte globulin (ATG) therapy is an established form of treatment for aplastic anaemia and has also been used as prophylaxis against graft rejection of bone marrow and renal allografts. Administration of ATG preparations has been associated with many mild clinical reactions, as have other forms of immunomodulatory therapy. However, serious adverse effects appear to be rare. We report a case of rapidly progressive fibrosing alveolitis and thyrotoxicosis in relation to ATG therapy, highlighting its potential toxicity and emphasising that its administration should be undertaken by experienced physicians in specialised centres. |
| Keywords: | Aplastic anaemia Antithymocyte globulin Fibrosing alveolitis Goitre Thyrotoxicosis |
| 本文献已被 SpringerLink 等数据库收录！ | |